Effectiveness of the 10-valent pneumococcal conjugate vaccine against radiographic pneumonia among children in rural Bangladesh: A case-control study.
Asia
Bangladesh
Child
Infant
Pneumococcal vaccines
Radiography
Respiratory tract infections
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
29 09 2020
29 09 2020
Historique:
received:
21
01
2020
revised:
13
08
2020
accepted:
14
08
2020
pubmed:
3
9
2020
medline:
28
4
2021
entrez:
3
9
2020
Statut:
ppublish
Résumé
Pneumococcal conjugate vaccine (PCV) effectiveness against radiographic pneumonia in South Asia is unknown. Bangladesh introduced PCV10 in 2015 using a three dose primary series (3 + 0). We sought to measure PCV10 effectiveness for two or more vaccine doses on radiographic pneumonia among vaccine-eligible children in rural Bangladesh. We conducted a matched case-control study over two years from 2015 to 2017 using clinic and community controls in three subdistricts of Sylhet, Bangladesh. Cases were vaccine eligible 3-35 month olds at Upazila Health Complex outpatient clinics with World Health Organization-defined radiographic primary endpoint pneumonia (radiographic pneumonia). Clinic controls were matched to cases within a one week time window by age, sex, and clinic and had an illness unlikely to be Streptococcus pneumoniae; community controls were healthy and similarly matched within a one week time window by age and sex, and distance from the clinic. We estimated adjusted vaccine effectiveness (aVE) using conditional logistic regression. We matched 1262 cases with 2707 clinic and 2461 community controls. Overall, aVE using clinic controls was 21.4% (95% confidence interval, -0.2%, 38.4%) for ≥2 PCV10 doses and among 3-11 month olds was 47.3% (10.5%, 69.0%) for three doses. aVE increased with higher numbers of doses in clinic control sets (p = 0.007). In contrast, aVE using community controls was 7.6% (95% confidence interval, -22.2%, 30.0%) for ≥2 doses. We found vaccine introduction in the study area faster and less variable than expected with 75% coverage on average, which reduced power. Information bias may also have affected community controls. Clinic control analyses show PCV10 prevented radiographic pneumonia in Bangladesh, especially among younger children receiving three doses. While both analyses were underpowered, community control enrollment - compared to clinic controls - was more difficult in a complex, pluralistic healthcare system. Future studies in comparable settings may consider alternative study designs.
Sections du résumé
BACKGROUND
Pneumococcal conjugate vaccine (PCV) effectiveness against radiographic pneumonia in South Asia is unknown. Bangladesh introduced PCV10 in 2015 using a three dose primary series (3 + 0). We sought to measure PCV10 effectiveness for two or more vaccine doses on radiographic pneumonia among vaccine-eligible children in rural Bangladesh.
METHODS
We conducted a matched case-control study over two years from 2015 to 2017 using clinic and community controls in three subdistricts of Sylhet, Bangladesh. Cases were vaccine eligible 3-35 month olds at Upazila Health Complex outpatient clinics with World Health Organization-defined radiographic primary endpoint pneumonia (radiographic pneumonia). Clinic controls were matched to cases within a one week time window by age, sex, and clinic and had an illness unlikely to be Streptococcus pneumoniae; community controls were healthy and similarly matched within a one week time window by age and sex, and distance from the clinic. We estimated adjusted vaccine effectiveness (aVE) using conditional logistic regression.
RESULTS
We matched 1262 cases with 2707 clinic and 2461 community controls. Overall, aVE using clinic controls was 21.4% (95% confidence interval, -0.2%, 38.4%) for ≥2 PCV10 doses and among 3-11 month olds was 47.3% (10.5%, 69.0%) for three doses. aVE increased with higher numbers of doses in clinic control sets (p = 0.007). In contrast, aVE using community controls was 7.6% (95% confidence interval, -22.2%, 30.0%) for ≥2 doses. We found vaccine introduction in the study area faster and less variable than expected with 75% coverage on average, which reduced power. Information bias may also have affected community controls.
CONCLUSIONS
Clinic control analyses show PCV10 prevented radiographic pneumonia in Bangladesh, especially among younger children receiving three doses. While both analyses were underpowered, community control enrollment - compared to clinic controls - was more difficult in a complex, pluralistic healthcare system. Future studies in comparable settings may consider alternative study designs.
Identifiants
pubmed: 32873404
pii: S0264-410X(20)31076-8
doi: 10.1016/j.vaccine.2020.08.035
pmc: PMC7520553
pii:
doi:
Substances chimiques
10-valent pneumococcal conjugate vaccine
0
Pneumococcal Vaccines
0
Vaccines, Conjugate
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6508-6516Subventions
Organisme : FIC NIH HHS
ID : K01 TW009988
Pays : United States
Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [EDM, SA, NHC, SJR, AMK, ADR, AAMH, FP, NS, MER, MH, HBS, AQ, NB, MS, LHM, WC, and AHB reports grants from Bill and Melinda Gates Foundation, grants from GlaxoSmithKline, during the conduct of the study.].
Références
Gates Open Res. 2018 Apr 26;2:21
pubmed: 29984359
Lancet. 2013 Apr 20;381(9875):1405-1416
pubmed: 23582727
Pediatr Infect Dis J. 2014 Jan;33 Suppl 2:S140-51
pubmed: 24336056
Lancet Glob Health. 2019 Jan;7(1):e47-e57
pubmed: 30497986
Pediatr Infect Dis J. 2009 Jun;28(6):455-62
pubmed: 19483514
Lancet Glob Health. 2018 Jul;6(7):e744-e757
pubmed: 29903376
Clin Infect Dis. 2017 Jun 15;64(suppl_3):S253-S261
pubmed: 28575359
Thorax. 2015 Dec;70(12):1149-55
pubmed: 26092924
N Engl J Med. 2003 Oct 2;349(14):1341-8
pubmed: 14523142
Pediatr Radiol. 2017 Oct;47(11):1399-1404
pubmed: 29043423
Pediatr Infect Dis J. 2007 Jul;26(7):565-71
pubmed: 17596795
Vaccine. 2017 Jun 5;35(25):3295-3302
pubmed: 28442231
Lancet. 2017 Dec 17;388(10063):3027-3035
pubmed: 27839855
Bull World Health Organ. 2005 May;83(5):353-9
pubmed: 15976876
Lancet. 2005 Mar 26-Apr 1;365(9465):1139-46
pubmed: 15794968
Vaccine. 2017 Jun 5;35(25):3303-3308
pubmed: 28442230
Lancet Infect Dis. 2018 Nov;18(11):1191-1210
pubmed: 30243584
BMJ Open Respir Res. 2019 Apr 15;6(1):e000393
pubmed: 31179000
Pediatr Infect Dis J. 2014 Jan;33 Suppl 2:S119-29
pubmed: 24336054
Lancet Infect Dis. 2017 Sep;17(9):965-973
pubmed: 28601421